Trifoliate Bio: Initiating Phase II clinical trial of RSV-hMPV-PIV3 respiratory syncytial virus combined vaccine candidate

The Clover Biopharmaceuticals announcement that the respiratory co-administration vaccine candidates SCB-1022 and SCB-1033, based on the company's self-developed Trimer-Tag vaccine development platform and developed with the Pre-F trimer subunit recombinant protein, have completed the enrollment of the first batch of subjects in Australia and officially started Phase 2 clinical trials.